Notable Reporting: bluebird bio Inc Can’t Be More Safe. Trades Significantly Higher

Notable Reporting: bluebird bio Inc Can't Be More Safe. Trades Significantly Higher

The stock of bluebird bio Inc (NASDAQ:BLUE) is a huge mover today! About 705,175 shares traded hands. bluebird bio Inc (NASDAQ:BLUE) has risen 29.13% since March 2, 2016 and is uptrending. It has outperformed by 20.87% the S&P500.
The move comes after 7 months positive chart setup for the $2.79 billion company. It was reported on Oct, 5 by We have $124.05 PT which if reached, will make NASDAQ:BLUE worth $1.93 billion more.

Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on November, 2. They expect $-1.48 earnings per share, down 25.42% or $0.30 from last year’s $-1.18 per share. After $-1.59 actual earnings per share reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -6.92% EPS growth.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Out of 13 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 77% are positive. bluebird bio has been the topic of 26 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by TH Capital on Thursday, November 5. On Saturday, August 22 the stock rating was maintained by JP Morgan with “Overweight”. The firm earned “Buy” rating on Friday, August 28 by Roth Capital. Leerink Swann initiated the stock with “Outperform” rating in Wednesday, February 3 report. As per Monday, December 7, the company rating was downgraded by Morgan Stanley. The rating was downgraded by Bank of America to “Neutral” on Monday, December 7. The stock of bluebird bio Inc (NASDAQ:BLUE) earned “Buy” rating by Jefferies on Friday, October 23. Cantor Fitzgerald initiated bluebird bio Inc (NASDAQ:BLUE) on Friday, June 3 with “Hold” rating. Oppenheimer initiated the stock with “Outperform” rating in Tuesday, October 20 report. The firm earned “Buy” rating on Saturday, August 15 by Roth Capital.

According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.34, from 1.34 in 2016Q1. The ratio dived, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Tiverton Asset Mgmt Lc has invested 0.54% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Teacher Retirement Of Texas has 5,114 shares for 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has 49,767 shares for 0.03% of their US portfolio. Arrowpoint Asset Limited Liability Co accumulated 560,164 shares or 0.49% of the stock. Blackrock Institutional Na has 902,966 shares for 0.01% of their US portfolio. Tiaa Cref Management Limited Liability Corporation last reported 0.01% of its portfolio in the stock. Tocqueville Asset Mgmt L P holds 0.03% or 52,800 shares in its portfolio. Moreover, Metropolitan Life Insurance Ny has 0.01% invested in bluebird bio Inc (NASDAQ:BLUE) for 27,042 shares. Public Employees Retirement Association Of Colorado has 7,118 shares for 0% of their US portfolio. Natl Planning reported 4,440 shares or 0.02% of all its holdings. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 1,465 shares. The Pennsylvania-based Federated Investors Pa has invested 0% in bluebird bio Inc (NASDAQ:BLUE). Swiss National Bank & Trust has 0% invested in the company for 59,707 shares. Qvt Lp last reported 0.18% of its portfolio in the stock. Co Of Vermont holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 245 shares.

More recent bluebird bio Inc (NASDAQ:BLUE) news were published by: which released: “Why bluebird bio Inc. Jumped Monday” on September 12, 2016. Also published the news titled: “Why bluebird bio Inc. Jumped Again Today” on September 15, 2016.‘s news article titled: “3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August” with publication date: September 09, 2016 was also an interesting one.

BLUE Company Profile

bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment